SELLAS Life Sciences Group, Inc. - Common Stock (SLS)
3.4600
-0.4000 (-10.36%)
NASDAQ · Last Trade: Jan 11th, 10:23 PM EST
Detailed Quote
Previous Close
3.860
Open
3.540
Bid
3.530
Ask
3.540
Day's Range
3.230 - 3.650
52 Week Range
0.8505 - 5.177
Volume
17,564,958
Market Cap
54.92M
PE Ratio (TTM)
-12.36
EPS (TTM)
-0.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
13,705,559
Chart
About SELLAS Life Sciences Group, Inc. - Common Stock (SLS)
Sellas Life Sciences Group Inc is a biotechnology company focused on the development of innovative immunotherapies for the treatment of cancer. The company is dedicated to advancing its therapeutic candidates through clinical trials, aiming to address unmet medical needs in oncology. By leveraging proprietary technology and scientific expertise, Sellas seeks to provide patients with effective treatment options that harness the body’s immune system to target and combat cancerous cells. Their pipeline includes various late-stage candidates designed to offer new hope for better outcomes in cancer care. Read More
Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS.
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a
The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
The company said its cancer drug SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax.
SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference.
In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock.
SELLAS Life Sciences (SLS) reported Q2 2025 EPS of -$0.07, beating estimates, with no revenue. Cash position strengthened to $25.3M. Clinical trials progress highlighted, including REGAL Phase 3 AML study. Stock rose slightly post-earnings.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
